Physician profile
Margot Chima
NPI 1982055752
$8,674.51
in general payments reported to CMS, 2019-2025
28 companies · $2,466 in 2025
The $2,466 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $600 · 2021: $335 · 2022: $1,450 · 2023: $1,559 · 2024: $1,574 · 2025: $2,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,411 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,410.64 |
| Education | $189.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,207.50 | 2019-2025 | Skyrizi, Rinvoq |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $815.95 | 2019-2025 | Arazlo, Jublia, Siliq |
| Janssen Biotech, INC. | $756.26 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $731.61 | 2020-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $646.72 | 2021-2025 | Winlevi, Ilumya |
| Genzyme Corporation | $635.75 | 2022-2025 | |
| Incyte Corporation | $591.21 | 2021-2025 | Opzelura |
| Pfizer INC. | $490.94 | 2020-2025 | |
| Lilly USA, LLC | $414.29 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $380.77 | 2020-2025 | Nemluvio, Aklief, Dysport |
| E.R. Squibb & Sons, L.L.C. | $296.48 | 2022-2024 | Sotyktu |
| Amgen INC. | $274.44 | 2019-2023 | Otezla |
| Dermavant Sciences, INC. | $228.73 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $193.80 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $144.02 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $117.99 | 2019-2020 | |
| Leo Pharma INC. | $109.00 | 2024-2025 | Adbry |
| Allergan, INC. | $97.33 | 2019 | |
| Arcutis Biotherapeutics, INC. | $95.51 | 2023-2025 | Zoryve |
| Ucb, INC. | $91.85 | 2022-2025 | Cimzia, Bimzelx |
| Almirall LLC | $77.31 | 2019-2025 | Klisyri |
| Organon LLC | $68.67 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.25 | 2024 | Spevigo |
| Mayne Pharma Commercial LLC | $53.06 | 2023-2025 | |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $20.52 | 2025 | Ycanth |
| Botanix Sb INC | $20.13 | 2025 | Sofdra |
| Journey Medical Corporation | $14.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margot Chima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.